Ji-Young Lee1, Jae Eun Lee2, Judith T Moskowitz3, Daniel J Feaster1, Torsten B Neilands4, Samantha E Dilworth4, Allan Rodriguez5, Adam W Carrico6. 1. Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, FL, USA. 2. College of Health Sciences, Jackson State University, Jackson, MS, USA. 3. Northwestern University Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. 4. School of Medicine, University of California, San Francisco, San Francisco, CA, USA. 5. Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA. 6. Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, FL, USA. Electronic address: a.carrico@miami.edu.
Abstract
BACKGROUND: Evidence-based interventions are needed to address the use of stimulants such as methamphetamine as a driver of onward HIV transmission and faster clinical HIV progression among sexual minority men. Prior randomized controlled trials with people living with HIV who use substances indicate that financial incentives provided during contingency management (CM) are effective for achieving short-term reductions in stimulant use and HIV viral load. However, the benefits of CM are often not maintained after financial incentives for behavior change end. PURPOSE: Data from a recently completed randomized controlled trial with 110 sexual minority men living with HIV who use methamphetamine was leveraged to examine mediators of the efficacy of a positive affect intervention for extending the benefits of CM. METHODS: An autoregressive cross-lagged model was fit to determine if reductions in HIV viral load were mediated by intervention-related increases in positive affect and decreases in stimulant use measured in four waves over 15 months. RESULTS: Higher baseline positive affect predicted significantly lower self-reported stimulant use immediately following the 3-month CM intervention period, even after controlling for self-reported stimulant use at baseline. Moreover, decreased stimulant use emerged as an independent predictor of long-term reductions HIV viral load at 15 months, even after adjusting for HIV viral load at baseline and the residual effect of the positive affect intervention. CONCLUSIONS: Findings underscore the importance of durable reductions in stimulant use as a primary intervention target that is essential for optimizing the clinical and public health benefits of HIV treatment as prevention.
BACKGROUND: Evidence-based interventions are needed to address the use of stimulants such as methamphetamine as a driver of onward HIV transmission and faster clinical HIV progression among sexual minority men. Prior randomized controlled trials with people living with HIV who use substances indicate that financial incentives provided during contingency management (CM) are effective for achieving short-term reductions in stimulant use and HIV viral load. However, the benefits of CM are often not maintained after financial incentives for behavior change end. PURPOSE: Data from a recently completed randomized controlled trial with 110 sexual minority men living with HIV who use methamphetamine was leveraged to examine mediators of the efficacy of a positive affect intervention for extending the benefits of CM. METHODS: An autoregressive cross-lagged model was fit to determine if reductions in HIV viral load were mediated by intervention-related increases in positive affect and decreases in stimulant use measured in four waves over 15 months. RESULTS: Higher baseline positive affect predicted significantly lower self-reported stimulant use immediately following the 3-month CM intervention period, even after controlling for self-reported stimulant use at baseline. Moreover, decreased stimulant use emerged as an independent predictor of long-term reductions HIV viral load at 15 months, even after adjusting for HIV viral load at baseline and the residual effect of the positive affect intervention. CONCLUSIONS: Findings underscore the importance of durable reductions in stimulant use as a primary intervention target that is essential for optimizing the clinical and public health benefits of HIV treatment as prevention.
Authors: Judith T Moskowitz; Adam W Carrico; Larissa G Duncan; Michael A Cohn; Elaine O Cheung; Abigail Batchelder; Lizet Martinez; Eisuke Segawa; Michael Acree; Susan Folkman Journal: J Consult Clin Psychol Date: 2017-03-23
Authors: Adam W Carrico; Elise D Riley; Mallory O Johnson; Edwin D Charlebois; Torsten B Neilands; Robert H Remien; Marguerita A Lightfoot; Wayne T Steward; Lance S Weinhardt; Jeffrey A Kelly; Mary Jane Rotheram-Borus; Stephen F Morin; Margaret A Chesney Journal: J Acquir Immune Defic Syndr Date: 2011-02-01 Impact factor: 3.731
Authors: Walter Gόmez; David Olem; Rick Andrews; Michael V Discepola; Patricia Ambrose; Samantha E Dilworth; Adam W Carrico Journal: Cogn Behav Pract Date: 2017-09-11
Authors: Robin M Nance; J A Chris Delaney; Jane M Simoni; Ira B Wilson; Kenneth H Mayer; Bridget M Whitney; Frances M Aunon; Steven A Safren; Michael J Mugavero; W Christopher Mathews; Katerina A Christopoulos; Joseph J Eron; Sonia Napravnik; Richard D Moore; Benigno Rodriguez; Bryan Lau; Rob J Fredericksen; Michael S Saag; Mari M Kitahata; Heidi M Crane Journal: Ann Intern Med Date: 2018-08-21 Impact factor: 25.391
Authors: Linda Bolier; Merel Haverman; Gerben J Westerhof; Heleen Riper; Filip Smit; Ernst Bohlmeijer Journal: BMC Public Health Date: 2013-02-08 Impact factor: 3.295
Authors: Hasina Samji; Angela Cescon; Robert S Hogg; Sharada P Modur; Keri N Althoff; Kate Buchacz; Ann N Burchell; Mardge Cohen; Kelly A Gebo; M John Gill; Amy Justice; Gregory Kirk; Marina B Klein; P Todd Korthuis; Jeff Martin; Sonia Napravnik; Sean B Rourke; Timothy R Sterling; Michael J Silverberg; Stephen Deeks; Lisa P Jacobson; Ronald J Bosch; Mari M Kitahata; James J Goedert; Richard Moore; Stephen J Gange Journal: PLoS One Date: 2013-12-18 Impact factor: 3.240
Authors: Alexsandra Andrawis; James Tapa; Ivo Vlaev; Daniel Read; Kelly Ann Schmidtke; Eric P F Chow; David Lee; Christopher K Fairley; Jason J Ong Journal: Curr HIV/AIDS Rep Date: 2022-08-05 Impact factor: 5.495